David Meek is headed to Paris. Ipsen, which had seen its top ranks roiled earlier this year, named the oncology chief of the short-lived Baxalta as its new CEO. Meek had helped steer Baxalta into a string of new cancer drug deals, which were happening even after Shire announced that it had completed a deal to acquire the company. “He will focus on strategy, on the continuation of the Group transformation plan and on operations,” an Ipsen spokesperson tells Endpoints, confirming that Meek will be relocating to the company’s HQ in Boulogne Billancourt. “He will be tasked with ensuring the development of the specialty care activities as well as primary care, and with pursuing the group internationalization in the US and China.” Meek’s deals involved hundreds of millions of upfront dollars for pacts with Symphogen, Precision BioSciences and others.
Get Endpoints News in your inbox
Newsletters for those who discover, develop, and market drugs. Join 13,000+ biopharma pros who read Endpoints News every day. Free subscription.
Subscribe to Endpoints
John Carroll, Editor and Co-Founder
We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.